Literature DB >> 2913084

A retrospective study of bone changes in adults treated with etretinate.

L Halkier-Sørensen1, J Andresen.   

Abstract

Ninety patients aged 17 to 80 years were treated with etretinate for disorders of keratinization and were studied for bone changes. The treatment lasted from 0.1 to 7.9 years, mean 2.4 years. The average dosage of etretinate was 0.57 mg/kg/day (range 0.21 to 1.32 mg/kg/day), and the total dose was 31 gm (range 1 to 197 gm). Standard radiographs of the axial and peripheral skeleton were evaluated. The films of 44 patients showed skeletal abnormalities such as periosteal thickening, hyperostosis of the vertebral column, disk degeneration, osteoporosis, calcification of the spinal ligaments, and slender long bones. The present data indicate that the risk of skeletal disorders in adults treated with etretinate is significant (44 of 90), but that the severity of changes is minor.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2913084     DOI: 10.1016/s0190-9622(89)70012-8

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  3 in total

Review 1.  Comparative tolerability of systemic treatments for plaque-type psoriasis.

Authors:  Stacy L McClure; Jayme Valentine; Kenneth B Gordon
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 2.  Recognition and treatment of psoriasis. Special considerations in elderly patients.

Authors:  C Bonifati; M Carducci; A Mussi; L D'Auria; F Ameglio
Journal:  Drugs Aging       Date:  1998-03       Impact factor: 3.923

3.  Unusual cortical bone features in a patient with gorlin-goltz syndrome: a case report.

Authors:  Adam Domonkos Tarnoki; David Laszlo Tarnoki; Katalin Klara Kiss; Pal Bata; Kinga Karlinger; Andras Banvolgyi; Norbert Wikonkal; Viktor Berczi
Journal:  Iran J Radiol       Date:  2014-10-20       Impact factor: 0.212

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.